|
US3117142A
(en)
|
1961-03-01 |
1964-01-07 |
Roussel Uclaf |
Novel preparation of estradiol and estrone
|
|
US3169134A
(en)
|
1963-03-21 |
1965-02-09 |
Searle & Co |
2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
|
|
BE754111A
(fr)
|
1969-07-29 |
1971-01-29 |
Upjohn Co |
Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
|
|
US3943124A
(en)
|
1970-12-17 |
1976-03-09 |
Gordon Hanley Phillipps |
Chemical compounds
|
|
US3983111A
(en)
|
1972-05-05 |
1976-09-28 |
Glaxo Laboratories Limited |
Steroidal anaesthetics of the pregnane and 19-norpregnane series
|
|
GB1430942A
(en)
|
1972-05-05 |
1976-04-07 |
Glaxo Lab Ltd |
21-substituted 3alpha-hydroxy pregnanes
|
|
US3865939A
(en)
|
1973-02-23 |
1975-02-11 |
Procter & Gamble |
Edible oils having hypocholesterolemic properties
|
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
|
GB1570394A
(en)
|
1976-01-06 |
1980-07-02 |
Glaxo Lab Ltd |
11-acyloxy-3-hydroxy steroids
|
|
US4192871A
(en)
|
1976-01-06 |
1980-03-11 |
Glaxo Laboratories Limited |
Chemical compounds
|
|
GB1581234A
(en)
|
1976-04-05 |
1980-12-10 |
Glaxo Operations Ltd |
11a - amino - 3a - hydroxysteroids
|
|
SE8600632D0
(sv)
|
1986-02-13 |
1986-02-13 |
Kabivitrum Ab |
Novel pharmaceutical composition
|
|
US5120723A
(en)
|
1987-08-25 |
1992-06-09 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
|
US5319115A
(en)
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
|
US5719197A
(en)
|
1988-03-04 |
1998-02-17 |
Noven Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
EP0603312A4
(en)
|
1991-09-13 |
1995-06-07 |
Cocensys Inc |
NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
|
|
JP4008024B2
(ja)
|
1993-05-24 |
2007-11-14 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
Ｇａｂａａレセプター複合体と相互作用させるための化合物
|
|
EP0656365B1
(en)
|
1993-12-02 |
1997-04-09 |
Akzo Nobel N.V. |
Substituted 2beta-morpholinoandrostane derivatives
|
|
US5939545A
(en)
|
1994-02-14 |
1999-08-17 |
Cocensys, Inc. |
Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
|
|
DK1038880T3
(da)
|
1994-02-14 |
2008-03-03 |
Euro Celtique Sa |
Androstaner og pregnaner til allosterisk modulering af GABA-receptor
|
|
JP3696884B2
(ja)
|
1994-03-25 |
2005-09-21 |
アイソテクニカ、インコーポレーテッド |
ジュウテリウム化による薬物の効能の増強
|
|
WO1996003421A1
(en)
|
1994-07-21 |
1996-02-08 |
Pharmacia & Upjohn Company |
Neurologically active aminosteroids
|
|
GEP20002033B
(en)
*
|
1994-11-23 |
2000-04-10 |
Cocensys Inc Us |
Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor
|
|
CA2223996A1
(en)
|
1995-06-06 |
1996-12-19 |
Cocensys, Inc. |
Neuroactive steroids of the androstane and pregnane series
|
|
US6780853B1
(en)
|
1995-06-06 |
2004-08-24 |
Euro-Celtique S.A. |
Neuroactive steroids of the androstane and pregnane series
|
|
EP0840612A1
(en)
|
1995-07-24 |
1998-05-13 |
Trustees Of Boston University |
Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
|
|
WO1998005337A1
(en)
|
1996-08-01 |
1998-02-12 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
|
US7630757B2
(en)
|
1997-01-06 |
2009-12-08 |
Flint Hills Scientific Llc |
System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
|
|
US5874418A
(en)
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
|
US6046177A
(en)
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
US6316613B1
(en)
|
1997-07-25 |
2001-11-13 |
Beckman Coulter, Inc. |
Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
|
|
US6245757B1
(en)
|
1997-10-03 |
2001-06-12 |
Research Corporation Technologies, Inc. |
Use of progestins to treat ischemic event
|
|
WO1999045931A1
(en)
|
1998-03-11 |
1999-09-16 |
Baeckstroem Torbjoern |
Epiallopregnanolone in the treatment of cns disorders
|
|
US20020198174A1
(en)
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
|
US6376531B1
(en)
|
1998-11-13 |
2002-04-23 |
Rupert Charles Bell |
Method of treatment using deuterium compounds
|
|
US20030236236A1
(en)
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
|
WO2001032170A1
(en)
*
|
1999-09-13 |
2001-05-10 |
Swope David M |
Composition and method for decreasing neurologic symptomatology
|
|
EP1104760B1
(en)
|
1999-12-03 |
2003-03-12 |
Pfizer Products Inc. |
Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
|
|
US6613308B2
(en)
|
2000-09-19 |
2003-09-02 |
Advanced Inhalation Research, Inc. |
Pulmonary delivery in treating disorders of the central nervous system
|
|
US20020072509A1
(en)
|
2000-10-11 |
2002-06-13 |
Stein Donald Gerald |
Methods for the treatment of a traumatic central nervous system injury
|
|
EP1216713A1
(en)
|
2000-12-20 |
2002-06-26 |
Schering Aktiengesellschaft |
Compositions of estrogen-cyclodextrin complexes
|
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
|
CA2443266A1
(en)
|
2001-02-13 |
2002-08-22 |
University Of Florida |
A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
|
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
CA2641760A1
(en)
|
2001-05-24 |
2002-11-28 |
Alexza Pharmaceuticals, Inc. |
Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
|
|
EP1392260A2
(en)
|
2001-05-24 |
2004-03-03 |
Alexza Molecular Delivery Corporation |
Delivery of benzodiazepines through an inhalation route
|
|
JP2003063965A
(ja)
|
2001-06-13 |
2003-03-05 |
Otsuka Pharmaceut Factory Inc |
注射用シロスタゾール水性製剤
|
|
SE0104423D0
(sv)
*
|
2001-12-27 |
2001-12-27 |
Umecrine Ab |
Pregnane steroids and their use in the treatment of CNS disorders
|
|
CA2472184C
(en)
|
2002-01-14 |
2011-04-19 |
David Mark Lucas |
Magnetically detectable latex articles
|
|
US20040138187A1
(en)
|
2002-08-28 |
2004-07-15 |
Reading Christopher L. |
Therapeutic treatment methods
|
|
US20040132826A1
(en)
*
|
2002-10-25 |
2004-07-08 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
|
US9339508B2
(en)
|
2003-01-17 |
2016-05-17 |
Mapreg |
Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
|
|
US7781421B2
(en)
|
2003-05-29 |
2010-08-24 |
Washington University |
Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
|
|
WO2005011612A2
(en)
|
2003-07-31 |
2005-02-10 |
The Research Foundation Of State University Of New York |
Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
|
|
GB0321607D0
(en)
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
US7892483B2
(en)
|
2004-03-12 |
2011-02-22 |
Cipla Limited |
Sterilization process
|
|
US20090118248A1
(en)
|
2004-04-23 |
2009-05-07 |
Euro-Celtique S.A. |
3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
|
|
EP1591455A1
(en)
*
|
2004-04-29 |
2005-11-02 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Essential tremor diagnostic and treatment
|
|
ITMI20041763A1
(it)
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
Nuove formulazioni iniettabili contenenti progesterone
|
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
|
WO2006037016A2
(en)
*
|
2004-09-27 |
2006-04-06 |
The Regents Of The University Of California |
Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
|
EP2471536A1
(en)
|
2004-09-29 |
2012-07-04 |
Harbor BioSciences, Inc. |
Steroid analogs and characterization and treatment methods
|
|
WO2006088894A2
(en)
|
2005-02-15 |
2006-08-24 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
|
RS52471B
(sr)
|
2005-03-24 |
2013-02-28 |
Emory University |
Režimi doziranja za lečenje traumatske povrede mozga progesteronom
|
|
AU2006235318A1
(en)
|
2005-04-07 |
2006-10-19 |
Hythiam, Inc. |
Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP1959966B1
(en)
|
2005-11-28 |
2020-06-03 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone formulations and methods for the making and use thereof
|
|
US20070287931A1
(en)
|
2006-02-14 |
2007-12-13 |
Dilorenzo Daniel J |
Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
|
|
JP2010502722A
(ja)
|
2006-09-08 |
2010-01-28 |
ブレインセルス，インコーポレイティド |
４−アシルアミノピリジン誘導体を含む組み合わせ
|
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
|
US20090203658A1
(en)
|
2007-01-08 |
2009-08-13 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
|
US20090074677A1
(en)
|
2007-01-08 |
2009-03-19 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
|
US7813811B2
(en)
|
2007-02-08 |
2010-10-12 |
Neuropace, Inc. |
Refillable reservoir lead systems
|
|
DK3461503T3
(da)
|
2007-04-11 |
2022-02-14 |
Biomarin Pharm Inc |
Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
|
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
|
EP2167098B1
(en)
|
2007-06-11 |
2018-09-05 |
University Of Southern California |
Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
|
|
CA2698172C
(en)
*
|
2007-06-15 |
2014-02-18 |
Cook, Kevin M. |
Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
|
|
GB0711948D0
(en)
|
2007-06-20 |
2007-08-01 |
Bionature E A Ltd |
Neurosteriod compounds
|
|
US20100316678A1
(en)
|
2007-06-28 |
2010-12-16 |
Cnsbio Pty Ltd. |
Combination methods and compositions for treatment of neuropathic pain
|
|
EP2254577A1
(en)
|
2007-12-26 |
2010-12-01 |
Eisai R&D Management Co., Ltd. |
Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
|
|
RU2470642C2
(ru)
|
2008-01-03 |
2012-12-27 |
Байомарин Фармасьютикл Инк. |
Аналоги птерина для лечения состояния, чувствительного к вн4
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US8729070B2
(en)
|
2008-02-20 |
2014-05-20 |
Targia Pharmaceuticals |
CNS pharmaceutical compositions and methods of use
|
|
CZ301216B6
(cs)
|
2008-07-10 |
2009-12-09 |
Ústav organické chemie a biochemie Akademie ved CR, v. v. i. |
Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
|
|
PL2356109T3
(pl)
|
2008-10-10 |
2017-07-31 |
Vm Discovery, Inc. |
Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób
|
|
CN102300566A
(zh)
|
2008-11-30 |
2011-12-28 |
O·扎查尔 |
血管收缩剂的皮肤应用
|
|
US20110306579A1
(en)
|
2009-01-30 |
2011-12-15 |
Emory University |
Methods of neuroprotection using neuroprotective steroids and a vitamin d
|
|
US20120142645A1
(en)
*
|
2009-03-17 |
2012-06-07 |
Marx Christine E |
Neuroactive steroid compositions and methods of use for lowering cholesterol
|
|
US20110152840A1
(en)
|
2009-12-23 |
2011-06-23 |
Drugtech Corporation |
Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
|
|
RU2574022C2
(ru)
|
2010-01-21 |
2016-01-27 |
Дробридж Фармасьютикалз Пти Лтд. |
Анестезирующий состав
|
|
JP5832547B2
(ja)
|
2010-11-03 |
2015-12-16 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
薬剤を含有する針カニューレ
|
|
US20130309306A1
(en)
|
2010-12-01 |
2013-11-21 |
The Regents Of The University Of California |
Intrapulmonary benzodiazepine for the treatment and prevention of seizures
|
|
CZ303443B6
(cs)
|
2011-02-15 |
2012-09-12 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
|
|
US9388210B2
(en)
|
2011-02-25 |
2016-07-12 |
Washington University |
Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
|
FR2973031B1
(fr)
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
|
US9084797B2
(en)
|
2011-05-23 |
2015-07-21 |
Besins Healthcare Luxembourg Sarl |
Progesterone treatment for improving sleep quality
|
|
KR20130002292A
(ko)
|
2011-06-28 |
2013-01-07 |
주식회사 비보존 |
다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
|
|
CA2843436A1
(en)
|
2011-07-29 |
2013-02-07 |
The Regents Of The University Of California |
Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
|
|
WO2013036835A1
(en)
|
2011-09-08 |
2013-03-14 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
US10478505B2
(en)
|
2011-09-23 |
2019-11-19 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
|
CN113234114A
(zh)
|
2011-10-14 |
2021-08-10 |
萨奇治疗股份有限公司 |
3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
|
|
CA2856592C
(en)
|
2011-11-29 |
2017-05-30 |
Amino Up Chemical Co., Ltd. |
Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent
|
|
CA2862076C
(en)
|
2012-01-23 |
2020-04-21 |
Sage Therapeutics, Inc. |
Neuroactive steroid formulations and methods of treating cns disorders
|
|
WO2013188792A2
(en)
|
2012-06-15 |
2013-12-19 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2014028398A2
(en)
|
2012-08-13 |
2014-02-20 |
The Regents Of The University Of California |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
|
|
PL2887944T3
(pl)
*
|
2012-08-21 |
2022-02-21 |
Sage Therapeutics, Inc. |
Allopregnanolon do leczenia lekoopornego stanu padaczkowego
|
|
US9765110B2
(en)
|
2012-10-08 |
2017-09-19 |
Washington University |
Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
|
US9757391B2
(en)
|
2012-11-09 |
2017-09-12 |
Goodchild Investments Pty Ltd |
Neuroactive steroids and their use to facilitate neuroprotection
|
|
JP2016501876A
(ja)
*
|
2012-11-30 |
2016-01-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ステロイドの抗痙攣活性
|
|
SG10201706063UA
(en)
|
2012-12-18 |
2017-09-28 |
Univ Washington |
Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
|
|
WO2014108808A2
(en)
|
2013-01-09 |
2014-07-17 |
Henry James Lorne |
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
|
|
WO2014169831A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
|
|
WO2014169836A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
|
WO2014169832A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
|
MX362543B
(es)
|
2013-04-17 |
2019-01-24 |
Sage Therapeutics Inc |
Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
|
|
HRP20210610T1
(hr)
|
2013-07-19 |
2021-05-28 |
Sage Therapeutics, Inc. |
Neuroaktivni steroidi, pripravci i njihove uporabe
|
|
PT3035940T
(pt)
|
2013-08-23 |
2019-01-28 |
Sage Therapeutics Inc |
Esteroides neuroativos, composições e seus usos
|
|
SG10201803812TA
(en)
|
2014-05-29 |
2018-06-28 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2015195962A1
(en)
|
2014-06-18 |
2015-12-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
EP4275748A3
(en)
|
2014-10-16 |
2024-01-03 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
EP3885352B1
(en)
|
2014-10-16 |
2024-11-27 |
Sage Therapeutics, Inc. |
A compound, compositions thereof and this compound for use in methods of treating cns disorders
|
|
RS60343B1
(sr)
|
2014-11-27 |
2020-07-31 |
Sage Therapeutics Inc |
Kompozicije i postupci za lečenje poremećaja cns-a
|
|
SMT202100113T1
(it)
|
2015-01-26 |
2021-05-07 |
Sage Therapeutics Inc |
Composizioni e metodi per trattare disturbi del snc
|
|
CN115487313A
(zh)
|
2015-02-06 |
2022-12-20 |
马瑞纳斯制药公司 |
静脉内加奈索酮制剂及其用途
|
|
EP3258939B1
(en)
|
2015-02-20 |
2022-09-07 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
EP3280420B1
(en)
|
2015-04-10 |
2024-03-27 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
MA45276A
(fr)
|
2015-06-18 |
2018-04-25 |
Sage Therapeutics Inc |
Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
|
|
GB2541015A
(en)
|
2015-08-06 |
2017-02-08 |
Ge Oil & Gas Uk Ltd |
Subsea flying lead
|
|
JP6957455B2
(ja)
|
2015-10-14 |
2021-11-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
ベータ細胞の複製及び／または生存の亢進
|
|
MA43284A
(fr)
|
2015-11-20 |
2018-09-26 |
Sage Therapeutics Inc |
Composés et leurs méthodes d'utilisation
|
|
CN113616661A
(zh)
|
2016-03-08 |
2021-11-09 |
萨奇治疗股份有限公司 |
神经活性类固醇、其组合物及用途
|
|
AU2017296295B2
(en)
|
2016-07-11 |
2022-02-24 |
Sage Therapeutics, Inc. |
C7, C12, and C16 substituted neuroactive steroids and their methods of use
|
|
MA45599A
(fr)
|
2016-07-11 |
2019-05-15 |
Sage Therapeutics Inc |
Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
|
|
US20180042903A1
(en)
|
2016-08-11 |
2018-02-15 |
Ovid Therapeutics Inc. |
Methods and compositions for treatment of epileptic disorders
|
|
US20180050107A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Neurosteroid compositions and methods of use thereof
|
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
|
JOP20190022B1
(ar)
|
2016-08-23 |
2023-03-28 |
Sage Therapeutics Inc |
ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
|
|
NZ751690A
(en)
|
2016-09-07 |
2022-02-25 |
Glia Llc |
Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
|
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
|
WO2018169798A1
(en)
|
2017-03-11 |
2018-09-20 |
The Regents Of The University Of California |
Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
|
|
KR20190137839A
(ko)
|
2017-04-18 |
2019-12-11 |
마리누스 파마슈티컬스 인코포레이티드 |
지속 방출 주사용 뉴로스테로이드 제제
|
|
US20180338959A1
(en)
|
2017-05-24 |
2018-11-29 |
Ovid Therapeutics Inc. |
Treatment of depressive disorders
|
|
US11752115B2
(en)
|
2017-06-21 |
2023-09-12 |
The Board Of Trustees Of The University Of Illinois |
PPAR-alpha agonist treatment of neuropsychiatric disorders
|
|
US11992495B2
(en)
|
2017-06-23 |
2024-05-28 |
The Regents Of The University Of California |
Enhancing GABA's ability to modulate immune responses
|
|
WO2018237282A1
(en)
|
2017-06-23 |
2018-12-27 |
The Board Of Trustees Of The University Of Illinois |
Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
|
|
EP3678670A1
(en)
|
2017-09-07 |
2020-07-15 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
|
US20200276209A1
(en)
|
2017-09-11 |
2020-09-03 |
Sage Therapeutics, Inc. |
Methods of treating epilepsy or status epilepticus
|
|
AU2018334214A1
(en)
|
2017-09-14 |
2020-03-26 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
|
WO2019094724A1
(en)
|
2017-11-10 |
2019-05-16 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating genetic epileptic disoders
|
|
US20200291059A1
(en)
|
2017-12-08 |
2020-09-17 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
CN118271387A
(zh)
|
2017-12-22 |
2024-07-02 |
萨奇治疗股份有限公司 |
治疗cns疾病的组合物和方法
|
|
AU2018392093B2
(en)
|
2017-12-22 |
2024-02-01 |
Sage Therapeutics, Inc. |
Compositions and methods for treating CNS disorders
|
|
US11718642B2
(en)
|
2018-01-12 |
2023-08-08 |
Sage Therapeutics, Inc. |
Compositions and methods for treating CNS disorders
|
|
TW202014192A
(zh)
|
2018-05-04 |
2020-04-16 |
加拿大商阿爾宙斯製藥有限公司 |
神經類固醇衍生物及其用途
|
|
CN117959309A
(zh)
|
2018-06-12 |
2024-05-03 |
萨奇治疗股份有限公司 |
19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
|
|
EP4321519A3
(en)
|
2018-10-12 |
2024-05-01 |
Sage Therapeutics, Inc. |
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
|
|
MX2021004452A
(es)
|
2018-10-19 |
2021-08-11 |
Sage Therapeutics Inc |
Esteroides neuroactivos no saturados 9(11) y sus métodos de uso.
|
|
JP2022506944A
(ja)
|
2018-11-08 |
2022-01-17 |
ヴァーソナ セラピューティクス，インコーポレーテッド |
５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用
|
|
MX2021005992A
(es)
|
2018-11-21 |
2021-09-14 |
Certego Therapeutics Inc |
Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
|
|
TW202521129A
(zh)
|
2018-12-05 |
2025-06-01 |
美商賽吉醫療公司 |
神經活性類固醇及其使用方法
|
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
|
SG11202106306YA
(en)
|
2018-12-14 |
2021-07-29 |
Acerus Biopharma Inc |
Active ester derivatives of testosterone, compositions and uses thereof
|
|
US20220372067A1
(en)
|
2018-12-21 |
2022-11-24 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
|
|
TW202523658A
(zh)
|
2019-05-24 |
2025-06-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
|
AR119047A1
(es)
|
2019-05-31 |
2021-11-17 |
Sage Therapeutics Inc |
Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
|
|
CN114787174A
(zh)
|
2019-06-27 |
2022-07-22 |
萨奇治疗股份有限公司 |
用于治疗cns病症的组合物和方法
|
|
CA3143545A1
(en)
|
2019-06-27 |
2020-12-30 |
Sage Therapeutics, Inc. |
Compounds for treating cns disorders
|
|
US20230303616A9
(en)
|
2019-06-27 |
2023-09-28 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
CN114761019A
(zh)
|
2019-12-05 |
2022-07-15 |
萨奇治疗股份有限公司 |
19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
|
|
JP2023518411A
(ja)
|
2020-03-18 |
2023-05-01 |
セージ セラピューティクス， インコーポレイテッド |
神経刺激性ステロイド及びその使用方法
|
|
EP4125921A1
(en)
|
2020-03-25 |
2023-02-08 |
Sage Therapeutics, Inc. |
Use of agents for treatment of respiratory conditions
|
|
WO2021262836A1
(en)
|
2020-06-24 |
2021-12-30 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
|
|
AR123018A1
(es)
|
2020-07-20 |
2022-10-26 |
Sage Therapeutics Inc |
Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este
|
|
AU2021385335A1
(en)
|
2020-11-25 |
2023-06-29 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
WO2022165017A1
(en)
|
2021-01-28 |
2022-08-04 |
Sage Therapeutics, Inc. |
Use of neuroactive steroids for treatment of sexual dysfunction
|
|
US20240148756A1
(en)
|
2021-02-18 |
2024-05-09 |
Sage Therapeutics, Inc. |
Use of neuroactive steroid for treatment of sexual dysfunction
|
|
BR112023018607A2
(pt)
|
2021-03-17 |
2023-10-24 |
Sage Therapeutics Inc |
Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior
|
|
AU2022258203A1
(en)
|
2021-04-12 |
2023-10-26 |
Sage Therapeutics, Inc. |
Treatment of essential tremor
|
|
CA3217866A1
(en)
|
2021-04-29 |
2022-11-03 |
Sage Therapeutics, Inc. |
Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
|
|
IL307991A
(en)
|
2021-04-29 |
2023-12-01 |
Sage Therapeutics Inc |
19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression
|